Traws Pharma Stock Debt To Equity
| TRAW Stock | 5.02 0.31 5.82% |
Traws Pharma fundamentals help investors to digest information that contributes to Traws Pharma's financial success or failures. It also enables traders to predict the movement of Traws Stock. The fundamental analysis module provides a way to measure Traws Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Traws Pharma stock.
| Last Reported | Projected for Next Year |
Traws | Debt To Equity |
Traws Pharma Company Debt To Equity Analysis
Traws Pharma's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Traws Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Traws Pharma is extremely important. It helps to project a fair market value of Traws Stock properly, considering its historical fundamentals such as Debt To Equity. Since Traws Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Traws Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Traws Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
Traws Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Traws Pharma has a Debt To Equity of 0.0%. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The debt to equity for all United States stocks is 100.0% higher than that of the company.
Traws Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Traws Pharma's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Traws Pharma could also be used in its relative valuation, which is a method of valuing Traws Pharma by comparing valuation metrics of similar companies.Traws Pharma is currently under evaluation in debt to equity category among its peers.
Traws Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Traws Pharma from analyzing Traws Pharma's financial statements. These drivers represent accounts that assess Traws Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Traws Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 136.7M | 2.0B | 1.1B | 339.8M | 414.5M | 434.3M | |
| Enterprise Value | 113.9M | 2.0B | 1.0B | 301.0M | 393.7M | 412.8M |
Traws Fundamentals
| Return On Equity | -10.97 | ||||
| Return On Asset | -0.53 | ||||
| Operating Margin | (103.23) % | ||||
| Current Valuation | (8.03 M) | ||||
| Shares Outstanding | 25.31 M | ||||
| Shares Owned By Insiders | 14.62 % | ||||
| Shares Owned By Institutions | 11.40 % | ||||
| Number Of Shares Shorted | 7.71 K | ||||
| Price To Book | 1.67 X | ||||
| Price To Sales | 39.17 X | ||||
| Revenue | 226 K | ||||
| EBITDA | (20.28 M) | ||||
| Net Income | (18.95 M) | ||||
| Total Debt | 12.01 M | ||||
| Book Value Per Share | (4.17) X | ||||
| Cash Flow From Operations | (17.93 M) | ||||
| Short Ratio | 0.36 X | ||||
| Earnings Per Share | (5.95) X | ||||
| Target Price | 6.5 | ||||
| Number Of Employees | 17 | ||||
| Beta | 1.39 | ||||
| Market Capitalization | 8.85 M | ||||
| Total Asset | 22.68 M | ||||
| Retained Earnings | (482.63 M) | ||||
| Working Capital | 13.44 M | ||||
| Net Asset | 22.68 M |
About Traws Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Traws Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Traws Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Traws Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Traws Stock Analysis
When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.